Ruben Osnabrugge

Ruben Osnabrugge, MD PhD, is Partner and Chief Medical Officer at 415 Capital, where he combines clinical expertise with investment activities in innovative cardiovascular and medtech technologies. He focuses on identifying and supporting companies developing transformative interventional therapies and medical devices.

Ruben trained in cardiothoracic surgery and holds a PhD in cardiovascular medicine. His clinical background underpins his work at the intersection of medicine, technology, and investment, with a particular focus on the evaluation and translation of novel therapies into clinical practice.

In his role, Ruben is actively involved in the medical evaluation of emerging technologies, including the assessment of clinical data, patient selection, and procedural applicability. He contributes to clinical decision-making around individual patient suitability for interventional procedures and provides medical guidance to portfolio companies and clinical partners.

Alongside his medical responsibilities, Ruben leads and supports investment activities, including clinical due diligence, strategic evaluation, and ongoing portfolio engagement. His work bridges clinical insight and innovation to advance next-generation cardiovascular therapies.